秋水仙碱用于血管事件二级预防的长期试验:一项荟萃分析
BACKGROUND AND AIMS: Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary prevention of coronary artery disease.…
要点
- 获益来自心肌梗死、缺血性卒中和紧急血运重建减少。
核心结论
- 与安慰剂相比,秋水仙碱显著降低MACE、心肌梗死、缺血性卒中和紧急冠状动脉血运重建,支持其用于减少复发性心血管事件。
主要发现
- 心肌梗死、缺血性卒中和紧急冠状动脉血运重建的减少均有统计学意义(P < .05)。
临床怎么用
- 对于临床明显血管病(如心肌梗死后、卒中后)患者,可考虑使用秋水仙碱进行二级预防以减少复发性心血管事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary prevention of coronary artery disease. Two recently published randomized controlled trials (RCTs) investigating colchicine in the post-stroke and post-myocardial infarction (MI) populations warrant a re-evaluation of colchicine. New evidence was synthesized in a systematic review and meta-analysis to determine the long-term efficacy and safety of colchicine for the secondary prevention of vascular disease. METHODS: Randomized controlled trials comparing the incidence of cardiovascular events between patients with clinically manifest vascular disease randomized to colchicine vs. placebo and ≥12-month follow-up were included. The primary efficacy endpoint is major adverse cardiovascular events (MACE) and includes cardiovascular mortality, MI, ischaemic stroke, and urgent coronary revascularization. The DerSimonian and Laird random effects model was used to calculate pooled effect estimates. RESULTS: Six RCTs, with a pooled sample size of 21 800 patients, were included (colchicine n = 10 871; placebo n = 10 929). Over a follow-up of 12-34 months, colchicine reduced the incidence of MACE compared with placebo [pooled hazard ratio .75, 95% confidence interval (CI) .56-.93]. The reduction in cardiovascular events among colchicine patients was driven by reductions in MIs, ischaemic strokes, and urgent coronary revascularizations (P < .05 for all). No differences were detected for safety outcomes (P > .05 for all), including non-cardiovascular deaths (risk ratio 1.08, 95% CI .76-1.54). CONCLUSIONS: This updated meta-analysis of RCTs demonstrated a substantial reduction in MACE, MI, ischaemic stroke, and recurrent coronary revascularization with colchicine compared with placebo. Therefore, the results support the use of colchicine to reduce recurrent cardiovascular events.
引用
- Samuel M, Berry C, Dubé MP, et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025. PMID: 40314333. doi:10.1093/eurheartj/ehaf174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。